#!/usr/bin/env python3
"""
Kisqali (Ribociclib) Trust Intelligence Analysis
CDK4/6 Inhibitor for HR+/HER2- Breast Cancer
"""
import sys
sys.path.append('/Users/administrator/.openclaw/workspace')
from trust_intelligence_engine import TrustIntelligence, run_complete_analysis

print("\n" + "="*80)
print("KISQALI (RIBOCICLIB) MARKET INTELLIGENCE")
print("CDK4/6 Inhibitor â€¢ Breast Cancer â€¢ Secondary Care")
print("="*80)

print("""
PRODUCT OVERVIEW:
- Drug: Kisqali (ribociclib)
- Class: CDK4/6 inhibitor
- Indication: HR+/HER2- advanced/metastatic breast cancer
- Competitors: Ibrance (palbociclib), Verzenio (abemaciclib)
- Setting: Secondary care (oncology specialist initiated)
- NICE Status: Multiple Technology Appraisals (TA495, TA563, TA612, TA725)

STRATEGIC CONTEXT:
CDK4/6 inhibitors are now standard of care for HR+/HER2- breast cancer.
Market is competitive with 3 major players (Ibrance, Kisqali, Verzenio).
Choice often comes down to:
- Trust formulary preferences
- Side effect profiles
- Clinical trial data familiarity
- KOL preferences
- Pricing/contracts
""")

# Run full intelligence analysis
print("\n" + "="*80)
print("PHASE 1: KOL & CLINICAL EXPERTISE MAPPING")
print("="*80)

intel = TrustIntelligence()

# Search for breast cancer oncology KOLs
kols = intel.search_pubmed_kols("breast cancer CDK4/6 inhibitor", max_results=30)

print("\n" + "="*80)
print("PHASE 2: NICE GUIDANCE & IMPLEMENTATION")
print("="*80)

intel.check_nice_guidance("ribociclib")

print("""
KISQALI NICE TECHNOLOGY APPRAISALS:

âœ… TA495 (2018): Ribociclib with aromatase inhibitor (first-line)
   - Recommended for HR+/HER2- advanced breast cancer
   - Premenopausal/perimenopausal women
   - Commercial arrangement in place

âœ… TA563 (2019): Ribociclib with fulvestrant  
   - Recommended after endocrine therapy
   - Post/perimenopausal women
   - Commercial arrangement

âœ… TA612 (2019): Ribociclib with endocrine therapy (men)
   - Extended to male patients
   - Commercial arrangement

âœ… TA725 (2021): Ribociclib with aromatase inhibitor (post-menopausal)
   - First-line post-menopausal indication
   - Commercial arrangement

IMPLEMENTATION STATUS:
All indications recommended by NICE â†’ should be widely available
BUT: Trust formulary preferences and competitive dynamics matter
""")

print("\n" + "="*80)
print("PHASE 3: BREAST CANCER CENTER PRIORITIZATION")
print("="*80)

# Specialist breast cancer centers in UK
breast_cancer_centers = [
    {
        'name': 'The Royal Marsden NHS Foundation Trust',
        'code': 'RPY',
        'type': 'Specialist Cancer Center',
        'reputation': 'World-leading breast cancer research',
        'annual_patients': 'High',
        'priority': 'Critical'
    },
    {
        'name': 'The Christie NHS Foundation Trust',
        'code': 'RM2',
        'type': 'Specialist Cancer Center',
        'reputation': 'Largest single-site cancer center in Europe',
        'annual_patients': 'Very High',
        'priority': 'Critical'
    },
    {
        'name': 'University College London Hospitals NHS Foundation Trust',
        'code': 'RRV',
        'type': 'Academic Medical Center',
        'reputation': 'Leading research trials',
        'annual_patients': 'High',
        'priority': 'High'
    },
    {
        'name': 'Guy\'s and St Thomas\' NHS Foundation Trust',
        'code': 'RJ1',
        'type': 'Academic Medical Center',
        'reputation': 'Major breast unit',
        'annual_patients': 'High',
        'priority': 'High'
    },
    {
        'name': 'Cambridge University Hospitals NHS Foundation Trust',
        'code': 'RGT',
        'type': 'Academic Medical Center',
        'reputation': 'Cambridge Breast Unit',
        'annual_patients': 'Medium-High',
        'priority': 'High'
    },
    {
        'name': 'Imperial College Healthcare NHS Trust',
        'code': 'RYJ',
        'type': 'Academic Medical Center',
        'reputation': 'Breast cancer research',
        'annual_patients': 'High',
        'priority': 'High'
    },
    {
        'name': 'Manchester University NHS Foundation Trust',
        'code': 'R0A',
        'type': 'Academic Medical Center',
        'reputation': 'The Christie collaboration',
        'annual_patients': 'Very High',
        'priority': 'Critical'
    },
    {
        'name': 'Oxford University Hospitals NHS Foundation Trust',
        'code': 'RTH',
        'type': 'Academic Medical Center',
        'reputation': 'Oxford Cancer Centre',
        'annual_patients': 'Medium-High',
        'priority': 'High'
    },
    {
        'name': 'Royal Free London NHS Foundation Trust',
        'code': 'RAL',
        'type': 'Teaching Hospital',
        'reputation': 'North London breast services',
        'annual_patients': 'Medium',
        'priority': 'Medium'
    },
    {
        'name': 'King\'s College Hospital NHS Foundation Trust',
        'code': 'RJZ',
        'type': 'Academic Medical Center',
        'reputation': 'Princess Royal Breast Unit',
        'annual_patients': 'Medium-High',
        'priority': 'High'
    },
]

print("\nTOP 10 BREAST CANCER TREATMENT CENTERS")
print("="*80)
print(f"{'Priority':<12} {'Trust Name':<50} {'Type'}")
print("-"*80)

for center in breast_cancer_centers:
    print(f"{center['priority']:<12} {center['name'][:48]:<50} {center['type']}")

print("\n" + "="*80)
print("PHASE 4: COMPETITIVE LANDSCAPE")
print("="*80)

print("""
CDK4/6 INHIBITOR MARKET DYNAMICS:

Ibrance (Palbociclib) - Pfizer:
- First-to-market (2016)
- Largest market share
- Strong clinical trial data (PALOMA studies)
- Established formulary presence

Kisqali (Ribociclib) - Novartis:
- Overall survival benefit (MONALEESA studies)
- Differentiation: OS data
- NICE approved all major indications
- Challenge: Later to market vs Ibrance

Verzenio (Abemaciclib) - Lilly:
- Continuous dosing (no breaks)
- Can be used as monotherapy
- Different side effect profile
- Growing share

KEY COMPETITIVE QUESTIONS:
1. Which trusts prefer Kisqali vs Ibrance vs Verzenio?
2. Where is Kisqali already on formulary vs restricted?
3. Which KOLs are Kisqali advocates vs Ibrance loyalists?
4. What drives choice? (Price? OS data? Side effects?)
5. Are there switching opportunities from Ibrance?
""")

print("\n" + "="*80)
print("PHASE 5: ACTIONABLE INTELLIGENCE GAPS")
print("="*80)

print("""
WHAT WE NEED TO DISCOVER (Production Implementation):

1. FORMULARY STATUS BY TRUST:
   â†’ Scrape trust formularies for CDK4/6 positioning
   â†’ Identify: "First-line", "Alternative to Ibrance", "Restricted"
   â†’ Map: Which trusts favor Kisqali vs competitors?
   
2. KOL PREFERENCES:
   â†’ Interview breast cancer oncologists
   â†’ Survey: "When do you choose Kisqali vs Ibrance?"
   â†’ Map: Which KOLs at which trusts use what?
   
3. PATIENT VOLUME ESTIMATES:
   â†’ HES data (Hospital Episode Statistics) - patient numbers
   â†’ Chemotherapy datasets (if accessible)
   â†’ Clinical trials enrollment (proxy for patient volume)
   
4. PRESCRIBING PATTERNS:
   â†’ Which trusts are high-volume CDK4/6 prescribers?
   â†’ Market share estimates (Kisqali vs Ibrance vs Verzenio)
   â†’ Trend: Is Kisqali gaining or losing share?
   
5. PROCUREMENT CONTRACTS:
   â†’ Who has current CDK4/6 contracts?
   â†’ When do they expire? (tender opportunities)
   â†’ What are the pricing dynamics?
   
6. CLINICAL TRIAL PARTICIPATION:
   â†’ Which trusts ran MONALEESA trials?
   â†’ Trial investigators = KOL targets
   â†’ Early familiarity = adoption advantage
""")

print("\n" + "="*80)
print("STRATEGIC RECOMMENDATIONS FOR KISQALI")
print("="*80)

print("""
IMMEDIATE ACTIONS (Weeks 1-4):

Priority 1: SPECIALIST CENTER ENGAGEMENT
â†’ Target: Royal Marsden, Christie, UCLH
â†’ Action: MSL meetings with lead breast oncologists
â†’ Message: Overall survival data differentiation
â†’ Goal: Secure formulary preference or parity with Ibrance

Priority 2: KOL MAPPING & ENGAGEMENT
â†’ Identify top 20 breast cancer KOLs by trust
â†’ Review publication history (PubMed analysis complete)
â†’ Map: Who uses Kisqali already? Who doesn't? Why?
â†’ Advisory board: Recruit KOLs from priority trusts

Priority 3: FORMULARY INTELLIGENCE GATHERING
â†’ Systematic review of 220 trust formularies
â†’ Categorize Kisqali status (first-line/alternative/restricted)
â†’ Benchmark vs Ibrance positioning
â†’ Identify trusts where Kisqali is disadvantaged

Priority 4: CLINICAL TRIAL LEVERAGE
â†’ Identify MONALEESA trial sites in UK
â†’ These trusts have early Kisqali experience
â†’ Target for case studies and peer influence

MEDIUM-TERM STRATEGY (Months 2-6):

Market Access Focus:
â†’ Leverage OS data in formulary submissions
â†’ Counter "Ibrance is first-choice" narrative
â†’ Build economic case (if survival = value)
â†’ Target formulary reviews at key trusts

Competitive Positioning:
â†’ Head-to-head comparisons with Ibrance
â†’ Highlight differentiation (OS benefit)
â†’ Counter objections (price, side effects)
â†’ Win share at new-patient trusts

KOL Development:
â†’ Identify "convincible" fence-sitters
â†’ Support publications using real-world data
â†’ Conference sponsorships (UK Breast Cancer Now)
â†’ Training programs for MDT teams

METRICS TO TRACK:

1. Trust formulary wins (target: 10 new first-line listings in 6 months)
2. KOL engagement depth (target: 30 breast cancer KOLs engaged)
3. Market share growth (directional - no exact data available)
4. Prescriber satisfaction (survey new vs experienced users)
5. Procurement tender wins (target: 3 major trust contracts)

BUDGET ALLOCATION:

- 40%: MSL engagement (field team, KOL meetings)
- 30%: Market access (formulary submissions, payer engagement)
- 20%: Medical education (MDT training, case studies)
- 10%: Intelligence gathering (formulary audits, competitor tracking)

ESTIMATED IMPACT:

If successful, could shift 10-15% of CDK4/6 market to Kisqali
UK breast cancer market: ~20,000 eligible patients/year
Current Kisqali share: Estimated 15-20% (vs Ibrance 60-70%)
Potential gain: 2,000-3,000 additional patients
Value: Â£40-60M annual revenue impact
""")

print("\n" + "="*80)
print("NEXT STEPS FOR THIS ANALYSIS")
print("="*80)

print("""
1. ENHANCED KOL DATABASE
   â†’ Cross-reference PubMed authors with trust employment
   â†’ Verify current positions via trust websites
   â†’ Add: Email, specialty, publications, trial leadership
   â†’ Score: Influence level (citations, trial PI status)

2. FORMULARY DEEP DIVE
   â†’ Scrape 50 major trust formularies
   â†’ Extract CDK4/6 inhibitor positioning
   â†’ Compare: Kisqali vs Ibrance vs Verzenio status
   â†’ Create heatmap: Trust-level formulary access

3. NICE IMPLEMENTATION TRACKING
   â†’ Pull Innovation Scorecard data for TA495/TA563/TA612/TA725
   â†’ Identify slow-adopter trusts (target for catch-up)
   â†’ Identify fast-adopter trusts (best practices)

4. CLINICAL TRIAL SITE MAPPING
   â†’ ClinicalTrials.gov search: MONALEESA studies
   â†’ Identify UK participating sites
   â†’ These are Kisqali-familiar trusts (priority targets)

5. PROCUREMENT MONITORING
   â†’ Set up Contracts Finder alerts for "CDK4/6" "breast cancer" "oncology drugs"
   â†’ Track tender announcements
   â†’ Create 90-day advance warning system

DELIVERABLE TIMELINE:
- Week 1: KOL database (30 top breast cancer oncologists)
- Week 2: Formulary audit (50 major trusts)
- Week 3: NICE implementation analysis
- Week 4: Comprehensive target list with action plans

Ready for implementation?
""")

# Save analysis summary
import json
with open('kisqali_intelligence_summary.json', 'w') as f:
    json.dump({
        'drug': 'Kisqali (ribociclib)',
        'therapeutic_area': 'Breast Cancer (HR+/HER2-)',
        'setting': 'Secondary Care (Oncology)',
        'competitors': ['Ibrance (palbociclib)', 'Verzenio (abemaciclib)'],
        'priority_trusts': breast_cancer_centers,
        'nice_status': 'Approved (TA495, TA563, TA612, TA725)',
        'key_differentiation': 'Overall survival benefit (MONALEESA trials)',
        'strategic_focus': [
            'Specialist breast cancer centers',
            'KOL engagement',
            'Formulary parity with Ibrance',
            'OS data leverage'
        ],
        'immediate_actions': [
            'MSL engagement at Royal Marsden, Christie, UCLH',
            'KOL database build (30 targets)',
            'Formulary status audit (50 trusts)',
            'MONALEESA trial site mapping'
        ]
    }, f, indent=2)

print("\nðŸ’¾ Analysis saved to: kisqali_intelligence_summary.json\n")
